Selepressin与安慰剂对脓毒性休克患者无呼吸机和无升压药天数的影响:SEPSIS-ACT随机临床试验
这项适应性2b/3期随机临床试验纳入868例需要去甲肾上腺素超过5 μg/min的脓毒性休克成人患者,比较Selepressin三种剂量方案与安慰剂。试验因无效而提前终止,主要终点30天内无呼吸机和无升压药天数在Selepressin组与安慰剂组间无显著差异(15.0 vs 14.5,差异0.6,95%CI -1.3至2.4,P=0.30),关键次要终点亦无显著差异。
要点
- 在需要去甲肾上腺素>5 μg/min的脓毒性休克患者中,Selepressin未改善30天内无呼吸机和无升压药天数。
- 90天死亡率Selepressin组40.6% vs 安慰剂组39.4%,差异无统计学显著性(P=0.77)。
- 试验因无效在Part 1结束时提前终止。
核心结论
- 在接受去甲肾上腺素的脓毒性休克患者中,与安慰剂相比,Selepressin未能改善30天内无升压药和无呼吸机天数。
- 原文结论指出,需要进一步研究评估Selepressin对脓毒性休克其他以患者为中心结局的潜在作用。
研究设计与样本
- 适应性2b/3期随机临床试验,分为两部分,纳入需要去甲肾上腺素超过5 μg/min的脓毒性休克成人患者868例。
- Part 1使用贝叶斯算法调整随机化概率至不同Selepressin剂量方案,并触发向Part 2的转换,Part 2比较表现最佳的方案与安慰剂。
- 试验于2015年7月至2017年8月在比利时、丹麦、法国、荷兰和美国的63家医院进行,随访于2018年5月完成。
- 随机分配至Selepressin三种剂量方案(起始输注速率1.7、2.5和3.5 ng/kg/min;n=585)或安慰剂(n=283),均根据血流动力学参数调整持续输注。
- 868例随机患者中,828例接受了研究药物(平均年龄66.3岁;341例[41.2%]女性)构成主要分析队列,其中562例接受Selepressin三种方案之一,266例接受安慰剂,817例(98.7%)完成试验。
主要发现
- 主要终点30天内无呼吸机和无升压药天数:Selepressin组15.0 vs 安慰剂组14.5,差异0.6(95%CI -1.3至2.4),P=0.30,无显著差异。
- 90天死亡率:Selepressin组40.6% vs 安慰剂组39.4%,差异1.1%(95%CI -6.5%至8.8%),P=0.77,无显著差异。
- 无肾脏替代治疗天数:Selepressin组18.5 vs 安慰剂组18.2,差异0.3(95%CI -2.1至2.6),P=0.85,无显著差异。
- 无ICU天数:Selepressin组12.6 vs 安慰剂组12.2,差异0.5(95%CI -1.2至2.2),P=0.41,无显著差异。
- 不良事件率包括心脏心律失常(Selepressin组27.9% vs 安慰剂组25.2%)、心脏缺血(6.6% vs 5.6%)、肠系膜缺血(3.2% vs 2.6%)和外周缺血(2.3% vs 2.3%)。
关键数值与推荐
- 主要终点为开始研究药物后30天内无呼吸机和无升压药天数(死亡计为零天)。
- 关键次要终点为90天死亡率、无肾脏替代治疗天数和无ICU天数。
- Selepressin起始输注速率分别为1.7、2.5和3.5 ng/kg/min。
- 纳入标准要求去甲肾上腺素剂量超过5 μg/min。
- 研究中位药物持续时间为37.8小时(IQR 17.8-72.4)。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 试验因无效在Part 1结束时提前终止。
- 原文结论指出需要进一步研究评估Selepressin对脓毒性休克其他以患者为中心结局的潜在作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Norepinephrine, the first-line vasopressor for septic shock, is not always effective and has important catecholaminergic adverse effects. Selepressin, a selective vasopressin V1a receptor agonist, is a noncatecholaminergic vasopressor that may mitigate sepsis-induced vasodilatation, vascular leakage, and edema, with fewer adverse effects. OBJECTIVE: To test whether selepressin improves outcome in septic shock. DESIGN, SETTING, AND PARTICIPANTS: An adaptive phase 2b/3 randomized clinical trial comprising 2 parts that included adult patients (n = 868) with septic shock requiring more than 5 μg/min of norepinephrine. Part 1 used a Bayesian algorithm to adjust randomization probabilities to alternative selepressin dosing regimens and to trigger transition to part 2, which would compare the best-performing regimen with placebo. The trial was conducted between July 2015 and August 2017 in 63 hospitals in Belgium, Denmark, France, the Netherlands, and the United States, and follow-up was completed by May 2018. INTERVENTIONS: Random assignment to 1 of 3 dosing regimens of selepressin (starting infusion rates of 1.7, 2.5, and 3.5 ng/kg/min; n = 585) or to placebo (n = 283), all administered as continuous infusions titrated according to hemodynamic parameters. MAIN OUTCOMES AND MEASURES: Primary end point was ventilator- and vasopressor-free days within 30 days (deaths assigned zero days) of commencing study drug. Key secondary end points were 90-day mortality, kidney replacement therapy-free days, and ICU-free days. RESULTS: Among 868 randomized patients, 828 received study drug (mean age, 66.3 years; 341 [41.2%] women) and comprised the primary analysis cohort, of whom 562 received 1 of 3 selepressin regimens, 266 received placebo, and 817 (98.7%) completed the trial. The trial was stopped for futility at the end of part 1. Median study drug duration was 37.8 hours (IQR, 17.8-72.4). There were no significant differences in the primary end point (ventilator- and vasopressor-free days: 15.0 vs 14.5 in the selepressin and placebo groups; difference, 0.6 [95% CI, -1.3 to 2.4]; P = .30) or key secondary end points (90-day mortality, 40.6% vs 39.4%; difference, 1.1% [95% CI, -6.5% to 8.8%]; P = .77; kidney replacement therapy-free days: 18.5 vs 18.2; difference, 0.3 [95% CI, -2.1 to 2.6]; P = .85; ICU-free days: 12.6 vs 12.2; difference, 0.5 [95% CI, -1.2 to 2.2]; P = .41). Adverse event rates included cardiac arrhythmias (27.9% vs 25.2% of patients), cardiac ischemia (6.6% vs 5.6%), mesenteric ischemia (3.2% vs 2.6%), and peripheral ischemia (2.3% vs 2.3%). CONCLUSIONS AND RELEVANCE: Among patients with septic shock receiving norepinephrine, administration of selepressin, compared with placebo, did not result in improvement in vasopressor- and ventilator-free days within 30 days. Further research would be needed to evaluate the potential role of selepressin for other patient-centered outcomes in septic shock. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02508649.
引用
- Laterre PF, Berry SM, Blemings A, et al. Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. JAMA. 2019. PMID: 31577035. doi:10.1001/jama.2019.14607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。